MedTrace Logo

Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients

NCT07427537 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-02-23

No results posted yet for this study

Summary

This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).

Conditions

  • Cancer, Lung
  • Colon Neoplasm
  • Neuropathy;Peripheral

Interventions

DIAGNOSTIC_TEST

Assessment of blood concentrations of microRNAs

day 1, day 43, and day 155.

OTHER

Chemotherapy-induced peripheral neuropathy (CIPN) - grade

day 1, day 43, and day 155.

OTHER

Pain assessement

day 1, day 43, and day 155.

DIAGNOSTIC_TEST

Assessment of blood concentrations of neurofilament light chain

day 1, day 43, and day 155.

OTHER

Neuropathic pain assessment

day 1, day 43, and day 155.

OTHER

Chemotherapy-induced peripheral neuropathy (CIPN) - severity

day 1, day 43, and day 155.

Sponsors & Collaborators

  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • David BALAYSSAC · University Hospital, Clermont-Ferrand

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-29
Primary Completion
2028-07-31
Completion
2028-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07427537 on ClinicalTrials.gov